160 related articles for article (PubMed ID: 38332640)
1. New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.
Gangat N; Tefferi A
Am J Hematol; 2024 May; 99(5):978-981. PubMed ID: 38332640
[TBL] [Abstract][Full Text] [Related]
2. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
Tiribelli M; Morelli G; Bonifacio M
Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
[TBL] [Abstract][Full Text] [Related]
4. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
Mascarenhas JO; Verstovsek S
Cancer; 2022 Jul; 128(14):2717-2727. PubMed ID: 35385124
[TBL] [Abstract][Full Text] [Related]
5. Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis.
Ferreira Gomes G; Harrison C
Curr Hematol Malig Rep; 2023 Aug; 18(4):113-120. PubMed ID: 37195585
[TBL] [Abstract][Full Text] [Related]
6. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
7. Investigational non-JAK inhibitors for chronic phase myelofibrosis.
Bankar A; Gupta V
Expert Opin Investig Drugs; 2020 May; 29(5):461-474. PubMed ID: 32245330
[TBL] [Abstract][Full Text] [Related]
8. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.
Lee SS; Verstovsek S; Pemmaraju N
J Immunother Precis Oncol; 2021 Aug; 4(3):117-128. PubMed ID: 35663101
[TBL] [Abstract][Full Text] [Related]
11. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
[TBL] [Abstract][Full Text] [Related]
12. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
13. The safety of JAK kinase inhibitors for the treatment of myelofibrosis.
Coltro G; Vannucchi AM
Expert Opin Drug Saf; 2021 Feb; 20(2):139-154. PubMed ID: 33327810
[TBL] [Abstract][Full Text] [Related]
14. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
15. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
16. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
18. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
Bose P; Mesa RA
Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
[TBL] [Abstract][Full Text] [Related]
19. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
Liu JX; Chen W; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859
[TBL] [Abstract][Full Text] [Related]
20. Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
